查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016213

快速诊断市场：全球市场按产品类型、技术、最终用户和应用分類的预测 - 2026-2032 年

Rapid Diagnostics Market by Product Type, Technology, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，快速诊断市场价值将达到 190.8 亿美元，到 2026 年将成长至 210.1 亿美元，到 2032 年将达到 486.5 亿美元，复合年增长率为 14.30%。

主要市场统计数据
基准年 2025 190.8亿美元
预计年份：2026年 210.1亿美元
预测年份 2032 486.5亿美元
复合年增长率 (%) 14.30%

对影响快速诊断的趋势进行了权威说明，并解释了为什么在创新、监管和供应链之间进行策略协调现在至关重要。

快速诊断领域正处于临床紧迫性、技术创新和不断演变的医疗服务模式的交汇点，这要求价值链上的相关人员制定清晰的策略方向。分子检测、即时检测平台和检测化学的最新进展加速了检测的去中心化，使得在传统实验室之外也能进行早期检测和快速临床决策。同时，来自支付方的压力和临床医生的期望正在重新定义部署标准，处理能力、週转时间和可操作的结果报告已成为关键绩效指标。

检测技术、数位化整合、监管变革和供应链韧性等方面的整合进步如何重塑诊断的部署。

诊断领域正经历着一场变革性的转变，技术、监管和市场力量的整合正在重新定义检测的方式和地点。在技​​术层面，核酸扩增技术的进步、检测设备的微型化以及电子读取器的改进，正推动快速分子检测从中心检查室走向临床应用。同时，改良的侧向层析法和免疫检测法提高了检测的灵敏度和易用性，使其更适用于分散式应用。此外，数位化连接和云端分析正在将个体检测结果转化为可操作的群体层面洞察，从而促进远端临床医生的监督。

评估美国不断变化的关税政策对快速诊断产业在营运、财务和供应链方面的广泛影响，展望 2025 年及以后。

近期贸易政策调整和关税措施增加了全球快速诊断供应链的复杂性，其累积影响将持续到2025年，波及采购、製造和定价等各个环节。设备和耗材常用零件的进口关税上调，推高了接收成本，并可能挤压製造商的利润空间，促使他们重新谈判合同，并重新审视各销售管道的定价策略。为此，供应商正在探索替代采购管道，实现部分生产的本地化，并重新设计物料材料清单（BOM），以减少对关税敏感原材料的依赖。

将产品分类、检测技术、最终用户需求和临床应用与策略性产品和市场发布选择联繫起来的详细细分见解。

为了深入了解市场，必须专注于不同的产品类别、技术模式、终端用户环境和临床应用，每种类别都有其独特的市场接受趋势和营运限制。产品细分清楚地展现了仪器、试剂和耗材以及检测套组之间的差异。仪器既包括适用于集中式检查室的桌上型系统，也包括分散式或照护现场环境最佳化的携带式设备。这种差异会影响医疗机构的采购週期、维护需求和资本投资计画。

美洲、欧洲、中东和非洲以及亚太地区的区域市场动态决定了采用、监管和供应策略的差异。

区域趋势对需求模式、监管预期和供应链策略有显着影响，美洲、欧洲、中东和非洲以及亚太地区的趋势各不相同。在美洲，对支援医院网路和门诊系统的整合平台的需求日益增长，采购受到支付方报销规则以及对诊断设备和电子健康记录 (EHR) 之间互通性的强烈需求的影响。该地区也积极投资国内製造业产能和官民合作关係，以加强供应链。

在快速诊断领域，塑造平台整合、伙伴关係模式和製造韧性的企业级竞争和策略行动。

快速诊断领域的竞争格局由成熟的跨国製造商、细分领域的专业公司、试剂供应商和数位化原生平台供应商组成，每家公司都奉行着自己独特的策略。成熟的製造商利用其规模、丰富的产品系列和完善的分销网络服务于医院系统和实验室，而小规模的创新者则专注于创新的检测方式、精简的生产流程或数位医疗功能的整合，旨在抢占快速增长的细分市场。

为诊断领域的领导者提供切实可行的策略建议，以加强其产品组合、确保其价值链、展现临床价值并拓展经营模式。

诊断产业的领导者必须将市场洞察转化为具体行动，抓住机会，并降低风险。首先，企业应优先考虑在仪器、试剂和检测套组方面实现产品组合多元化，同时确保平台相容性，以最大限度地发挥产品应用潜力。投资于模组化设计和平台通用将缩短开发週期，并实现灵活的生产响应。其次，应透过多元化采购、地域多角化和策略性库存缓衝来重新评估供应链策略，以降低贸易政策波动和物流瓶颈带来的风险。

采用严谨的混合方法研究途径，结合关键相关人员的访谈、第二手资料的整合、供应链映射和情境建模，以获得可靠的见解。

这些研究成果透过与关键相关人员的对话、结构化的二次分析以及有针对性的情境建模，从多角度展现了快速诊断的现状。主要资讯来自对临床医生、检查室经理、采购专家和行业高管的访谈，从而获得了关于工作流程优先级、推广障碍和技术观点的第一手观点。二次分析整合了监管指南、已发表的临床文献、专利趋势和公共发展，将市场观察置于科学和合规的框架内。

全面概述了诊断技术创新、营运韧性、监管合规性和商业性执行之间面临的策略挑战。

总之，快速诊断生态系统呈现出机会与挑战并存的复杂局面，需要清晰的策略规划、强大的营运韧性和基于实证的商业化。分子诊断技术的进步、侧向层析方法的改进以及携带式设备的普及，正在扩大检测的覆盖范围，并使在传统检查室之外进行更快速的临床干预成为可能。同时，监管变化、支付方的期望以及贸易政策趋势，也为研发商和经销商带来了新的限制和挑战。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：快速诊断市场：依产品类型划分

  • 装置
    • 固定式
    • 可携式的
  • 试剂和耗材
  • 检测套组

第九章：快速诊断市场：依技术划分

  • 免疫检测
  • 横向流动化验
    • 竞争型
    • 三明治法
  • 分子诊断
    • 等温扩增
    • PCR

第十章 快速诊断市场：依最终使用者划分

  • 诊所
  • 居家照护
  • 医院
  • 检查室

第十一章 快速诊断市场：依应用领域划分

  • 心臟标记物
    • 肌酸激酶 Mb
    • 肌红蛋白
    • 肌钙蛋白
  • 糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 感染疾病
    • 细菌感染疾病
    • 寄生虫感染疾病
    • 病毒感染疾病
  • 肿瘤学

第十二章 快速诊断市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 快速诊断市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 快速诊断市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国快速诊断市场

第十六章：中国快速诊断市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • ACON Laboratories, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • QIAGEN NV
  • QuidelOrtho Corporation
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-035AB9C0DA79

The Rapid Diagnostics Market was valued at USD 19.08 billion in 2025 and is projected to grow to USD 21.01 billion in 2026, with a CAGR of 14.30%, reaching USD 48.65 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.08 billion
Estimated Year [2026] USD 21.01 billion
Forecast Year [2032] USD 48.65 billion
CAGR (%) 14.30%

An authoritative introduction to the dynamics shaping rapid diagnostics and why strategic alignment across innovation, regulation and supply chains matters now

The rapid diagnostics space sits at the intersection of clinical urgency, technological innovation, and shifting healthcare delivery models, demanding clear strategic orientation from stakeholders across the value chain. Recent advances in molecular assays, point-of-care platforms, and assay chemistries have accelerated the decentralization of testing, enabling earlier detection and faster clinical decision making outside traditional laboratory settings. Meanwhile, payer pressures and clinician expectations are reshaping the criteria for adoption, elevating throughput, turnaround time, and actionable result reporting as primary performance metrics.

As a consequence, manufacturers and service providers are navigating a more complex set of requirements: tighter regulatory scrutiny, rising demands for interoperability, and new business models that extend beyond product sales into data services and managed solutions. This environment favors organizations that can combine robust clinical validation with scalable manufacturing and resilient supply chains. At the same time, end users-from hospitals to home care-are increasingly motivated to integrate diagnostic outputs into clinical workflows and population health programs, which creates demand for flexible platforms and validated point-of-care assays.

In short, the introduction to this landscape emphasizes the need for informed strategic responses that bridge innovation, compliance, and commercial execution across multiple product and technology categories, while maintaining patient-centric outcomes and operational efficiency.

How convergent advances in assay technology, digital integration, regulatory evolution, and supply chain resilience are reshaping diagnostic deployment

The diagnostic landscape is undergoing transformative shifts driven by convergent technological, regulatory, and market forces that are redefining how and where tests are performed. Technologically, improvements in nucleic acid amplification methods, assay miniaturization, and readout electronics have enabled rapid molecular testing to move from centralized labs to point-of-care settings, while enhanced lateral flow formats and immunoassays have improved sensitivity and usability for decentralized applications. Simultaneously, digital connectivity and cloud-based analytics are turning discrete test results into actionable population-level insights and facilitating remote clinician oversight.

Regulatory pathways are also evolving to accommodate novel device formats and software-as-a-medical-device components, which accelerates time to market for well-documented platforms but raises compliance complexity for integrated solutions. Commercially, reimbursement frameworks and procurement preferences are shifting toward outcomes-based purchasing and bundled services, prompting vendors to rethink go-to-market approaches and strategic partnerships. Supply chain resilience has moved from a cost focus to a strategic imperative, with manufacturers diversifying sourcing and investing in regional production capabilities to mitigate disruption risk.

Taken together, these transformative shifts favor agile organizations that can align product innovation with clinical validation, regulatory foresight, and scalable manufacturing, while engaging payers and providers to demonstrate real-world value across care settings.

Assessing the broader operational, financial, and supply chain consequences of evolving United States tariff policies on rapid diagnostics through 2025 and beyond

Trade policy adjustments and tariff measures instituted in recent years have imposed a layer of complexity on global supply chains for rapid diagnostics, and their cumulative effect continues to reverberate through procurement, manufacturing, and pricing decisions into 2025. Increased import duties on components commonly used in instruments and consumables can elevate landed costs and squeeze manufacturer margins, prompting contract renegotiations and a reassessment of pricing strategies across commercial channels. In response, suppliers are evaluating alternative sourcing, localizing portions of production, and redesigning product bill-of-materials to reduce exposure to tariff-sensitive inputs.

Beyond direct cost impact, tariffs introduce administrative friction at ports of entry, extending lead times for critical reagents and instrument components and increasing working capital requirements for distributors and laboratories. Such delays can have downstream clinical consequences by affecting inventory planning and test availability, particularly for high-throughput or time-critical applications. Moreover, policy uncertainty around tariff schedules complicates long-range capital planning and investment in manufacturing capacity, which can slow decisions to scale new platforms or expand production lines.

At the same time, selective policy carve-outs for medical goods or negotiated exemptions can mitigate some pressure, while strategic nearshoring and collaborative supplier frameworks offer pathways to preserve product affordability and continuity of supply. Ultimately, organizations that proactively model tariff scenarios, diversify supplier portfolios, and invest in regulatory and customs expertise will be better positioned to sustain operations and protect access to essential diagnostic capabilities.

Deep segmentation insights linking product classes, assay technologies, end-user requirements, and clinical applications to strategic product and go-to-market choices

A granular view of the market requires attention to distinct product classes, technology modalities, end-user settings, and clinical applications, each of which follows its own adoption dynamics and operational constraints. Product segmentation shows a clear differentiation between instruments, reagents and consumables, and test kits, where instruments encompass both benchtop systems suited to centralized laboratories and portable devices optimized for decentralized or point-of-care environments. This split influences procurement cycles, maintenance requirements, and capital expenditure planning for healthcare providers.

Technology segmentation reveals varied pathways for innovation and commercialization. Immunoassays maintain a central role in many routine workflows due to robust clinical utility, while lateral flow assay formats continue to evolve with competitive and sandwich architectures that improve sensitivity and result presentation for rapid screening. Molecular diagnostics, including both polymerase chain reaction workflows and isothermal amplification techniques, are driving higher-sensitivity detection in compact formats, enabling clinical-grade results outside of traditional lab settings.

End-user segmentation underscores divergent needs across clinics, home care environments, hospitals, and laboratories, with each setting demanding different validation standards, throughput capabilities, and workflow integration. Application-driven segmentation further clarifies clinical priorities: cardiac markers such as creatine kinase-MB, myoglobin, and troponin require rapid, high-specificity readouts for acute care; diabetes management differentiates between Type 1 and Type 2 needs for monitoring and diagnostic precision; infectious disease testing spans bacterial, parasitic, and viral targets with varied sample types and turnaround requirements; oncology applications often require high analytical sensitivity and linkage to downstream therapeutic pathways. These layered segments inform product design, regulatory strategies, and commercial targeting across the diagnostic ecosystem.

Regional market dynamics across the Americas, Europe, Middle East & Africa, and Asia-Pacific that dictate differentiated adoption, regulation, and supply strategies

Regional dynamics exert a profound influence on demand patterns, regulatory expectations, and supply chain strategies, with distinct trajectories observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, demand leans toward integrated platforms that support hospital networks and outpatient systems, with procurement influenced by payer reimbursement rules and a strong push for interoperability between diagnostics and electronic health records. This region also exhibits active investment in domestic manufacturing capacity and public-private partnerships to fortify supply chains.

Across Europe, the Middle East & Africa, regulatory harmonization efforts and variable healthcare infrastructure create heterogeneous market conditions that favor adaptable platforms and multi-modal assays. In some European markets, stringent regulatory oversight and centralized reimbursement mechanisms drive emphasis on rigorous clinical evidence, while in parts of the Middle East & Africa, infrastructure constraints heighten demand for robust, low-complexity, and transport-tolerant solutions.

The Asia-Pacific landscape is characterized by rapid adoption of decentralized testing and strong government-led initiatives to enhance local production, spanning large urban centers to rural networks. Diverse healthcare systems and varying levels of laboratory capacity create both scale opportunities and distribution challenges, encouraging strategic alliances with local players and investments in training and support services. Together, these regional nuances underline the need for differentiated commercial strategies, regulatory planning, and supply chain models that align with localized clinical and economic realities.

Competitive and strategic company-level behaviors shaping platform consolidation, partnership models, and manufacturing resilience in rapid diagnostics

Competitive dynamics in the rapid diagnostics space are shaped by a mix of established multinational manufacturers, niche specialists, reagent suppliers, and digitally native platform providers, each pursuing distinct strategic plays. Incumbent manufacturers leverage scale, broad product portfolios, and established distribution networks to serve hospital systems and reference laboratories, while smaller innovators focus on disruptive assay formats, streamlined manufacturing processes, or integration of digital health capabilities to capture pockets of rapid adoption.

Increasingly, strategic activity centers on partnerships and alliances that combine assay developers with instrument makers, data analytics firms, and logistics providers to deliver end-to-end solutions. Mergers and acquisitions remain a tactical path for acquiring complementary technologies or accelerating entry into new geographies, while licensing agreements and OEM arrangements provide flexible commercialization alternatives that reduce time-to-market. Companies are also investing in modular platform strategies that enable cross-application reuse of instrument bases, which supports faster assay rollouts and reduces per-unit production complexity.

Supply chain stewardship and regulatory expertise have become differentiators as organizations seek to ensure uninterrupted reagent availability and compliance across multiple jurisdictions. Firms that integrate clinical evidence generation, payer engagement, and scalable manufacturing are more successful at converting product innovation into sustainable market positions, while those that lag on service, support, or evidence development face adoption headwinds.

Actionable strategic recommendations for diagnostics leaders to strengthen portfolios, secure supply chains, demonstrate clinical value, and scale commercial models

Leaders in the diagnostics industry must translate market insights into concrete actions to capture opportunity and mitigate risk. First, organizations should prioritize portfolio diversification across instruments, reagents, and test kits while ensuring cross-platform compatibility to maximize addressable use cases. Investing in modular design and platform commonality reduces development cycle time and supports flexible manufacturing responses. Second, supply chain strategies should be reassessed through multi-sourcing, regionalization, and strategic inventory buffers to reduce exposure to trade policy shocks and logistical bottlenecks.

Third, vendors must deepen regulatory and clinical evidence capabilities by integrating real-world performance studies and health-economic analyses into product launches. Demonstrating outcomes and cost-effectiveness to payers accelerates coverage decisions and supports premium positioning. Fourth, commercialization models should shift toward value-driven offerings that bundle testing hardware with consumables, data services, and managed support to create recurring revenue and stronger customer relationships. Fifth, digital integration of diagnostics into electronic health records and telehealth workflows must be a priority to enhance utility and adoption in decentralized settings.

Finally, active engagement with policymakers and industry consortia can shape pragmatic trade and regulatory outcomes, protecting patient access while enabling sustainable business models. Executing these recommendations requires cross-functional alignment and disciplined investment prioritization to convert strategic intent into market advantage.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary evidence synthesis, supply chain mapping, and scenario modeling for robust insights

The research behind these insights combines primary stakeholder engagement, structured secondary analysis, and targeted scenario modeling to deliver a multidimensional view of the rapid diagnostics landscape. Primary inputs were collected through interviews with clinicians, laboratory directors, procurement experts, and industry executives, providing firsthand perspectives on workflow priorities, adoption barriers, and technology preferences. Secondary analysis synthesized regulatory guidance, published clinical literature, patent landscapes, and public policy developments to contextualize market-facing observations within scientific and compliance frameworks.

Supply chain mapping and supplier risk assessment were used to identify critical nodes and common points of disruption, while technology readiness evaluations distinguished near-term deployable platforms from early-stage innovations requiring additional validation. Tariff and trade impact was assessed through scenario-based modeling that considered likely policy permutations and their operational consequences, enabling pragmatic recommendations for mitigation.

Throughout, findings were triangulated across data sources and validated with subject-matter experts to ensure robustness. Quality assurance measures included traceability of primary quotes, cross-referencing regulatory citations, and iterative peer review to refine conclusions and ensure actionable relevance for stakeholders making commercial, investment, or procurement decisions.

Concluding synthesis of strategic imperatives that connect diagnostic innovation, operational resilience, regulatory alignment, and commercial execution

In conclusion, the rapid diagnostics ecosystem presents a compelling mix of opportunity and complexity that requires strategic clarity, operational resilience, and evidence-driven commercialization. Advances in molecular methods, improved lateral flow formats, and the proliferation of portable instrumentation are expanding testing access and enabling more immediate clinical interventions outside traditional laboratory settings. At the same time, regulatory change, payer expectations, and trade policy dynamics are creating new constraints and considerations for developers and distributors alike.

Organizations that succeed will be those that align product innovation with rigorous clinical validation, cultivate adaptive supply chains, and pursue commercial models that emphasize outcomes and recurring value. Regional nuance demands differentiated approaches to market entry and partnership, while tariff-related uncertainty highlights the importance of sourcing flexibility and customs expertise. Above all, an integrated strategy that marries technical excellence with pragmatic execution-covering manufacturing, regulatory, reimbursement, and clinician engagement-will be essential to translate technological promise into sustained impact on patient care.

These conclusions underscore the need for focused investments and cross-functional coordination to capture the gains offered by rapid diagnostics while safeguarding continuity of access and clinical utility.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rapid Diagnostics Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop
    • 8.1.2. Portable
  • 8.2. Reagents & Consumables
  • 8.3. Test Kits

9. Rapid Diagnostics Market, by Technology

  • 9.1. Immunoassay
  • 9.2. Lateral Flow Assay
    • 9.2.1. Competitive
    • 9.2.2. Sandwich
  • 9.3. Molecular Diagnostics
    • 9.3.1. Isothermal Amplification
    • 9.3.2. Pcr

10. Rapid Diagnostics Market, by End User

  • 10.1. Clinics
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Laboratories

11. Rapid Diagnostics Market, by Application

  • 11.1. Cardiac Markers
    • 11.1.1. Creatine Kinase Mb
    • 11.1.2. Myoglobin
    • 11.1.3. Troponin
  • 11.2. Diabetes
    • 11.2.1. Type 1 Diabetes
    • 11.2.2. Type 2 Diabetes
  • 11.3. Infectious Diseases
    • 11.3.1. Bacterial Infections
    • 11.3.2. Parasitic Infections
    • 11.3.3. Viral Infections
  • 11.4. Oncology

12. Rapid Diagnostics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Rapid Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rapid Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Rapid Diagnostics Market

16. China Rapid Diagnostics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. ACON Laboratories, Inc.
  • 17.7. Becton, Dickinson and Company
  • 17.8. Bio-Rad Laboratories, Inc.
  • 17.9. bioMerieux SA
  • 17.10. Danaher Corporation
  • 17.11. DiaSorin S.p.A.
  • 17.12. EKF Diagnostics Holdings plc
  • 17.13. F. Hoffmann-La Roche Ltd.
  • 17.14. Hologic, Inc.
  • 17.15. QIAGEN N.V.
  • 17.16. QuidelOrtho Corporation
  • 17.17. Siemens Healthineers AG
  • 17.18. Sysmex Corporation
  • 17.19. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BENCHTOP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PORTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TEST KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COMPETITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SANDWICH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY CREATINE KINASE MB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY MYOGLOBIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TROPONIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY BACTERIAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PARASITIC INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY VIRAL INFECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 197. GCC RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 203. GCC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GCC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. GCC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 207. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 230. G7 RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. G7 RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. G7 RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 235. G7 RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 236. G7 RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. G7 RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. G7 RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 239. G7 RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 240. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. NATO RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 242. NATO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 244. NATO RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 246. NATO RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 247. NATO RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. NATO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. NATO RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 250. NATO RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 251. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)